文献速递妇科

辅助治疗对Ⅰ期子宫癌肉瘤复发模式的影响

Impact of adjuvant therapy on recurrence patterns in stage I uterine carcinosarcoma.
PubMed 文献 · Gynecol Oncol · 2017-02-16

基于26家机构1192例子宫癌肉瘤回顾性队列中的443例Ⅰ期患者,分析辅助治疗模式与复发模式的关系。化疗是独立预后因素,降低局部复发(5年累积率8.7% vs 19.8%,调整HR 0.46)和远处复发(21.2% vs 38.0%,调整HR 0.41);化疗联合放疗在多个危险因素存在时降低局部复发(2.5% vs 21.8%,HR 0.12)。

要点

  • 辅助化疗是Ⅰ期子宫癌肉瘤局部复发(调整HR 0.46)和远处复发(调整HR 0.41)的独立预后因素。
  • 化疗联合放疗较单纯化疗降低局部复发未达统计学显著(5.1% vs 10.1%,调整HR 0.46,95%CI 0.13-1.58,P=0.22)。
  • 多个危险因素存在时,化疗联合放疗较单纯化疗降低局部复发(2.5% vs 21.8%,HR 0.12,95%CI 0.02-0.90,P=0.013)。

核心结论

  • 辅助化疗似乎可有效控制Ⅰ期子宫癌肉瘤的局部和远处复发;当肿瘤存在多个危险因素时,化疗联合放疗可能有效控制局部复发。

研究设计与样本

  • 回顾性队列研究,来自26家机构的1192例子宫癌肉瘤病例中选取443例Ⅰ期患者。
  • 分析初次全子宫切除术为基础的手术后辅助治疗模式与复发模式的相关性。

主要发现

  • 最常见辅助治疗为单纯化疗(41.5%),其次为化疗联合放疗(15.8%)和单纯放疗(8.4%)。
  • 远处复发为最常见复发模式(5年累积率28.1%),其次为局部复发(13.3%)。
  • 多因素分析中,化疗而非放疗是局部复发风险降低的独立预后因素(5年累积率8.7% vs 19.8%,调整HR 0.46,95%CI 0.25-0.83,P=0.01)。
  • 多因素分析中,化疗而非放疗是远处复发风险降低的独立预后因素(5年累积率21.2% vs 38.0%,调整HR 0.41,95%CI 0.27-0.62,P<0.001)。
  • 化疗联合放疗组较单纯化疗组5年累积局部复发率更低但未达统计学显著(5.1% vs 10.1%,调整HR 0.46,95%CI 0.13-1.58,P=0.22)。

临床怎么用

  • 作者认为辅助化疗似乎可有效控制Ⅰ期子宫癌肉瘤的局部和远处复发。
  • 作者认为当肿瘤存在多个危险因素时,化疗联合放疗可能有效控制局部复发。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To examine recurrence patterns in women with stage I uterine carcinosarcoma (UCS) stratified by adjuvant therapy pattern. METHODS: We examined 443 cases of stage I UCS derived from a retrospective cohort of 1192 UCS cases from 26 institutions. Adjuvant therapy patterns after primary hysterectomy-based surgery were correlated to recurrence patterns. RESULTS: The most common adjuvant therapy was chemotherapy alone (41.5%) followed by chemotherapy/radiotherapy (15.8%) and radiotherapy alone (8.4%). Distant-recurrence was the most common recurrence pattern (5-year cumulative rate, 28.1%) followed by local-recurrence (13.3%). On multivariate analysis, chemotherapy but not radiotherapy remained an independent prognostic factor for decreased risk of local-recurrence (5-year cumulative rates 8.7% versus 19.8%, adjusted-hazard ratio [HR] 0.46, 95% confidence interval [CI] 0.25-0.83, P=0.01) and distant-recurrence (21.2% versus 38.0%, adjusted-HR 0.41, 95%CI 0.27-0.62, P<0.001). The chemotherapy/radiotherapy group had a lower 5-year cumulative local-recurrence rate compared to the chemotherapy alone group but it did not reach statistical significance (5.1% versus 10.1%, adjusted-HR 0.46, 95%CI 0.13-1.58, P=0.22). Radiotherapy significantly decreased local-recurrence when tumors had high-grade carcinoma, sarcoma component dominance, and deep myometrial tumor invasion (all, P<0.05); and combining radiotherapy with chemotherapy was significantly associated with decreased local-recurrence compared to chemotherapy alone in the presence of multiple risk factors (5-year cumulative rates, 2.5% versus 21.8%, HR 0.12, 95%CI 0.02-0.90; P=0.013) but not in none/single factor (P=0.36). CONCLUSION: Adjuvant chemotherapy appears to be effective to control both local- and distant-recurrences in stage I UCS; adding radiotherapy to chemotherapy may be effective to control local-recurrence when the tumor exhibits multiple risk factors.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Matsuo K, Omatsu K, Ross MS, et al. Impact of adjuvant therapy on recurrence patterns in stage I uterine carcinosarcoma. Gynecol Oncol. 2017. PMID: 28215838. doi:10.1016/j.ygyno.2017.02.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。